Clinical characteristics, tumor-infiltrating lymphocytes, and prognosis in HER2-low breast cancer: A comparison study with HER2-zero and HER2-positive disease.
HER2-low
breast cancer
sTILs
survival
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
15
05
2023
received:
14
10
2022
accepted:
15
06
2023
medline:
1
9
2023
pubmed:
27
6
2023
entrez:
27
6
2023
Statut:
ppublish
Résumé
HER2-low breast cancer is a gradually recognized and unexplored group of diseases. We aimed to investigate the clinical and prognosis features and to identify the role of stromal tumor-infiltrating lymphocytes (sTILs) in this population. Consecutive primary breast cancer patients treated between January 2009 to June 2013 were retrospectively reviewed. HER2-low was defined as immunohistochemistry (IHC) 1+, or 2+ and fluorescence in situ hybridization (FISH) negative. sTILs were scored following the international guidelines. Clinicopathologic features and survival were compared according to HER2 and sTILs category. A total of 973 breast cancer patients were enrolled, including 615 (63.2%) HER2-low patients. HER2-low patients shared more similarity with HER2-0 cases in clinicopathological features. sTILs in HER2-Low patients was comparable to HER2-0 patients (p = 0.064), both significantly lower than HER2-positive ones (p < 0.001). Meanwhile, tumors with sTILs ≥50% accounted for the least proportion of HER2-low cases (p < 0.001). HER2 status had no significant influence on recurrence-free survival (RFS, p = 0.901) in the whole population. However, in the estrogen receptor (ER)-negative subgroup, HER2-low was related to worse RFS (p = 0.009) and OS (p = 0.001) compared with HER2-positive ones. sTILs increment was an independent favorable prognostic factor in the whole (OS, p = 0.003; RFS, p = 0.005) and HER2-low population (OS, p = 0.007; RFS, p = 0.009) after adjusted to clinicopathological parameters. HER2-low patients shared similar clinicopathological features with HER2-0 rather than HER2-positive cases and had relatively low sTILs. ER-negative/HER2-low patients had significantly inferior survival. sTILs increment was independently associated with favorable survival in the HER2-low group, suggesting a potential benefit from a novel treatment strategy.
Identifiants
pubmed: 37366301
doi: 10.1002/cam4.6290
pmc: PMC10469737
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
16264-16278Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancer Res Treat. 2019 Oct;51(4):1336-1346
pubmed: 30744321
Eur J Cancer. 2021 Sep;155:1-12
pubmed: 34311211
Annu Rev Med. 2011;62:233-47
pubmed: 20887199
J Clin Oncol. 2020 Jun 10;38(17):1887-1896
pubmed: 32058843
Cancer Res. 2013 Mar 1;73(5):1635-46
pubmed: 23442322
J Cancer Res Clin Oncol. 2016 Jun;142(6):1369-76
pubmed: 27008006
Breast Cancer. 2022 Mar;29(2):234-241
pubmed: 34622383
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Breast Cancer Res. 2021 Dec 14;23(1):112
pubmed: 34906198
Cancer Med. 2023 Aug;12(15):16264-16278
pubmed: 37366301
Breast Cancer Res Treat. 2021 Nov;190(1):155-163
pubmed: 34409551
Nat Med. 2000 Apr;6(4):443-6
pubmed: 10742152
J Clin Oncol. 2007 May 20;25(15):2127-32
pubmed: 17513820
Front Oncol. 2021 Jul 01;11:638619
pubmed: 34277399
Lancet Oncol. 2021 Aug;22(8):1151-1161
pubmed: 34252375
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
J Immunol. 2015 May 1;194(9):4379-86
pubmed: 25795760
Ann Oncol. 2019 Mar 1;30(3):418-423
pubmed: 30657852
Eur J Cancer. 2020 Mar;127:240-250
pubmed: 31956037
Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25
pubmed: 29024776
Ann Oncol. 2014 Aug;25(8):1544-50
pubmed: 24608200
Int J Clin Oncol. 2022 Feb;27(2):332-339
pubmed: 34661778
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
JAMA Oncol. 2022 Apr 01;8(4):1-4
pubmed: 35113160
Lancet Oncol. 2020 Apr;21(4):519-530
pubmed: 32171426
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
J Clin Oncol. 2013 Mar 1;31(7):860-7
pubmed: 23341518
Eur J Cancer. 2021 Sep;154:217-226
pubmed: 34293665
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Immunother Cancer. 2016 Oct 18;4:59
pubmed: 27777769
Am J Clin Pathol. 2019 Sep 9;152(4):479-485
pubmed: 31172196
Eur J Cancer. 2018 Jan;89:9-18
pubmed: 29223481
Cancers (Basel). 2021 Dec 01;13(23):
pubmed: 34885167
Lancet Oncol. 2019 Aug;20(8):1124-1135
pubmed: 31257177
Lancet. 2017 Mar 25;389(10075):1195-1205
pubmed: 28215665
J Clin Oncol. 2014 Nov 20;32(33):3744-52
pubmed: 25332249
Lancet Oncol. 2017 Jan;18(1):52-62
pubmed: 27964843
Science. 1989 May 12;244(4905):707-12
pubmed: 2470152
Sci Rep. 2022 Jul 28;12(1):12974
pubmed: 35902644
Int J Mol Sci. 2019 Mar 05;20(5):
pubmed: 30841523
Cancers (Basel). 2021 Jun 05;13(11):
pubmed: 34198891
J Clin Oncol. 2020 Feb 10;38(5):444-453
pubmed: 31821109
Eur J Med Res. 2022 Dec 17;27(1):293
pubmed: 36528658
NPJ Breast Cancer. 2021 Jan 4;7(1):1
pubmed: 33397968
Breast Cancer Res. 2015 Nov 17;17:140
pubmed: 26578067
Breast Cancer Res Treat. 2020 Sep;183(2):347-354
pubmed: 32621251
Lancet Oncol. 2018 Jan;19(1):40-50
pubmed: 29233559
J Natl Compr Canc Netw. 2021 May 01;19(5):484-493
pubmed: 34794122
BMC Cancer. 2020 Nov 25;20(1):1150
pubmed: 33238978
Semin Cancer Biol. 2021 Jul;72:123-135
pubmed: 32112814
JAMA Oncol. 2016 Jan;2(1):56-64
pubmed: 26469139
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
Arch Pathol Lab Med. 2007;131(1):18-43
pubmed: 19548375
Breast Cancer Res Treat. 2015 Jun;151(2):357-64
pubmed: 25926338
JAMA Oncol. 2015 Jul;1(4):448-54
pubmed: 26181252
Cancer Med. 2021 Nov;10(22):7921-7933
pubmed: 34562054